molnupiravir eidd 2801 Search Results


molnupiravir mpv  (MedChemExpress)
95
MedChemExpress molnupiravir mpv
Molnupiravir Mpv, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/molnupiravir+eidd+2801/Molnupiravir/pmc11745048-117-0-5
Average 95 stars, based on 1 article reviews
molnupiravir mpv - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier
molnupiravir  (TargetMol)
94
TargetMol molnupiravir
Validation of reporter assay using inhibitors of SARS-CoV-2 RdRp activity. HEK 293 cells and A549 cells were transiently transfected with the reporter vector and RdRp. After 24 h, the cells were treated with various concentrations of ( a ) remdesivir, ( b ) <t>molnupiravir,</t> ( c ) tenofovir, and ( d ) sofosbuvir. These compounds were added to the reporter vector and RdRp co-expressed cells, followed by an additional 24 h incubation to measure reporter activity (solid line) and cell viability (dotted line). The data represent the results of three independent experiments. Reporter activity was expressed as a percentage relative to the reporter and RdRp co-expressed group. Statistical significance is denoted as * p < 0.05, ** p < 0.01, and *** p < 0.001 compared to the reporter vector and RdRp co-expressed group.
Molnupiravir, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/molnupiravir+eidd+2801/EIDD-2801/pmc12106634-201-0-17
Average 94 stars, based on 1 article reviews
molnupiravir - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier
molnupiravir eidd 2801 efficacy against sars cov 2  (Experimental Pathology Laboratories Inc)
86
Experimental Pathology Laboratories Inc molnupiravir eidd 2801 efficacy against sars cov 2
Validation of reporter assay using inhibitors of SARS-CoV-2 RdRp activity. HEK 293 cells and A549 cells were transiently transfected with the reporter vector and RdRp. After 24 h, the cells were treated with various concentrations of ( a ) remdesivir, ( b ) <t>molnupiravir,</t> ( c ) tenofovir, and ( d ) sofosbuvir. These compounds were added to the reporter vector and RdRp co-expressed cells, followed by an additional 24 h incubation to measure reporter activity (solid line) and cell viability (dotted line). The data represent the results of three independent experiments. Reporter activity was expressed as a percentage relative to the reporter and RdRp co-expressed group. Statistical significance is denoted as * p < 0.05, ** p < 0.01, and *** p < 0.001 compared to the reporter vector and RdRp co-expressed group.
Molnupiravir Eidd 2801 Efficacy Against Sars Cov 2, supplied by Experimental Pathology Laboratories Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/molnupiravir+eidd+2801/2+2801+against+cov+efficacy+eidd+molnupiravir+sars/pm36535309-11-2-77
Average 86 stars, based on 1 article reviews
molnupiravir eidd 2801 efficacy against sars cov 2 - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier
molnupiravir (eidd-2801)  (Aladdin Scientific Corporation)
N/A
   Buy from Supplier

Image Search Results


Validation of reporter assay using inhibitors of SARS-CoV-2 RdRp activity. HEK 293 cells and A549 cells were transiently transfected with the reporter vector and RdRp. After 24 h, the cells were treated with various concentrations of ( a ) remdesivir, ( b ) molnupiravir, ( c ) tenofovir, and ( d ) sofosbuvir. These compounds were added to the reporter vector and RdRp co-expressed cells, followed by an additional 24 h incubation to measure reporter activity (solid line) and cell viability (dotted line). The data represent the results of three independent experiments. Reporter activity was expressed as a percentage relative to the reporter and RdRp co-expressed group. Statistical significance is denoted as * p < 0.05, ** p < 0.01, and *** p < 0.001 compared to the reporter vector and RdRp co-expressed group.

Journal: Scientific Reports

Article Title: Construction and validation of a cell based reporter assay for identifying inhibitors of SARS coronavirus 2 RNA dependent RNA polymerase activity

doi: 10.1038/s41598-025-03813-y

Figure Lengend Snippet: Validation of reporter assay using inhibitors of SARS-CoV-2 RdRp activity. HEK 293 cells and A549 cells were transiently transfected with the reporter vector and RdRp. After 24 h, the cells were treated with various concentrations of ( a ) remdesivir, ( b ) molnupiravir, ( c ) tenofovir, and ( d ) sofosbuvir. These compounds were added to the reporter vector and RdRp co-expressed cells, followed by an additional 24 h incubation to measure reporter activity (solid line) and cell viability (dotted line). The data represent the results of three independent experiments. Reporter activity was expressed as a percentage relative to the reporter and RdRp co-expressed group. Statistical significance is denoted as * p < 0.05, ** p < 0.01, and *** p < 0.001 compared to the reporter vector and RdRp co-expressed group.

Article Snippet: Molnupiravir (EIDD-2801, cat. No. T8309), tenofovir (cat. No. T1649), and sofosbuvir (Cat. No. T6676) were obtained from TargetMol (MA, USA).

Techniques: Biomarker Discovery, Reporter Assay, Activity Assay, Transfection, Plasmid Preparation, Incubation